Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications

Elevated COX-2 activity is associated with the development of chronic lung diseases leading to bronchial obstruction, including sarcoidosis. The aim of the study was to examine expression pattern of COX-2 messenger RNA (mRNA). Expression was performed by q-PCR method in bronchoalveolar lavage (BAL)...

Full description

Saved in:
Bibliographic Details
Published in:Inflammation 2016-08, Vol.39 (4), p.1302-1309
Main Authors: Kiszałkiewicz, Justyna, Piotrowski, Wojciech J., Pastuszak-Lewandoska, Dorota, Górski, Paweł, Antczak, Adam, Górski, Witold, Domańska-Senderowska, Daria, Migdalska-Sęk, Monika, Czarnecka, Karolina H., Nawrot, Ewa, Brzeziańska-Lasota, Ewa
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Bronchoalveolar Lavage Fluid - chemistry
Case-Control Studies
Cyclooxygenase 2 - genetics
Cyclooxygenase 2 - metabolism
Down-Regulation
Humans
Immunology
Internal Medicine
Lymphocytes - chemistry
Original Article
Pathology
Pharmacology/Toxicology
Rheumatology
RNA, Messenger - analysis
Sarcoidosis, Pulmonary - enzymology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated COX-2 activity is associated with the development of chronic lung diseases leading to bronchial obstruction, including sarcoidosis. The aim of the study was to examine expression pattern of COX-2 messenger RNA (mRNA). Expression was performed by q-PCR method in bronchoalveolar lavage (BAL) cells and peripheral blood (PB) lymphocytes in sarcoidosis patients ( n  = 61) and control group ( n  = 30). Analysis of COX-2 mRNA expression level in BAL fluid and PB revealed downregulation in sarcoidosis and control groups. In PB lymphocytes, the statistically significant difference between patients and controls was observed ( P  = 0.003, Mann–Whitney U test), with higher expression in patients. There were no statistically significant differences between patients without and with parenchymal involvement (stages I vs. II–IV), between patients with acute vs. insidious onset of disease and between patients with abnormal vs. normal spirometry ( P  > 0.05, Mann–Whitney U test). Results suggest that expression of COX-2 mRNA in patients with pulmonary sarcoidosis is not related to clinical classifications.
ISSN:0360-3997
1573-2576
DOI:10.1007/s10753-016-0362-y